Redeye comments on Klaria’s announcement earlier today regarding a SEK9.
Redeye leaves a research update following Klaria Pharma’s recently published Q4 2024 report.
Redeye leaves a research update following Klaria Pharma’s recent announcement of a licensing agreement with CNX Therapeutics for the marketi...
Redeye leaves a comment following Klaria’s recent announcement of a licensing agreement with CNX Therapeutics for the marketing and sale of ...
Redeye leaves a research update following Klaria Pharma’s recently published Q3 2024 report.
Redeye leaves a research update following Klaria Pharma’s recently published Q2 2024 report.
Redeye leaves a comment following today’s encouraging news that Klaria has received market authorization in key European markets for its lea...
Redeye leaves a research update following Klaria Pharma’s recently published Q1 2024 report.
Redeye leaves a research update following Klaria Pharma’s Q4 2023 report published earlier today.
Redeye leaves a comment on Klaria’s announcement of a signed bridge loan agreement with a term of two years.
Kvartalet i korthet Klaria Pharma stängde böcker för det tredje kvartalet i fredags och rapporten innehöll inga överraskningar.
Redeye leaves a research update following Klaria Pharma’s Q3 2023 report.
Redeye leaves a comment on yesterday’s news that Jesper Wiklund is stepping down as the CEO of Klaria Pharma and that the board has decided ...
Redeye comments on Klaria Pharma’s Q2 2023 report. Despite the recent rights issue at the end of 2022, which generated SEK59.
Redeye comments on Klaria Pharma’s Q1 2023 report. The company reports continued validation of its epinephrine alginate film.
Redeye comments on The Swedish Financial Supervisory Authority´s decision to initiate an investigation of Klaria Pharma.
Redeye initiates coverage of Klaria Pharma Holding AB, a Swedish biotech company, utilising its transmucoadhesive drug delivery technology p...
